Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.610 +0.020 (+1.26%)
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 164,206
Open 1.590
Bid (Size) 1.580 (4)
Ask (Size) 1.620 (3)
Prev. Close 1.590
Today's Range 1.590 - 1.620
52wk Range 0.8502 - 2.093
Shares Outstanding 26,289,087
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week
Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline. 
Via Benzinga
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga

Performance

YTD
+56.3%
+56.3%
1 Month
+3.2%
+3.2%
3 Month
+22.0%
+22.0%
6 Month
+26.8%
+26.8%
1 Year
-3.0%
-3.0%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
From Brodsky & Smith LLC
Via GlobeNewswire
LVTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lava Therapeutics N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang
Via Benzinga
This Constellation Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
Via Benzinga
On Wednesday, there are stocks with unusual volume. Let's take a look.
Via Chartmill
What's going on in today's session
Via Chartmill
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session.
Via Chartmill
LVTX Stock Earnings: LAVA Therapeutics Beats EPS for Q2 2024
Via InvestorPlace
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Announces Annual Meeting of Shareholders
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
From LAVA Therapeutics N.V.
Via GlobeNewswire
LVTX Stock Earnings: LAVA Therapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
From LAVA Therapeutics N.V.
Via GlobeNewswire
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
From LAVA Therapeutics N.V.
Via GlobeNewswire
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
Via FinancialNewsMedia
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Donald Trump Has Re-Entered The Chat)
Via Benzinga
Topics Government
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments
From FN Media Group LLC
Via GlobeNewswire

Frequently Asked Questions

Is LAVA Therapeutics N.V. - Ordinary Shares publicly traded?
Yes, LAVA Therapeutics N.V. - Ordinary Shares is publicly traded.
What exchange does LAVA Therapeutics N.V. - Ordinary Shares trade on?
LAVA Therapeutics N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares?
The ticker symbol for LAVA Therapeutics N.V. - Ordinary Shares is LVTX on the Nasdaq Stock Market
What is the current price of LAVA Therapeutics N.V. - Ordinary Shares?
The current price of LAVA Therapeutics N.V. - Ordinary Shares is 1.610
When was LAVA Therapeutics N.V. - Ordinary Shares last traded?
The last trade of LAVA Therapeutics N.V. - Ordinary Shares was at 09/29/25 03:59 PM ET
What is the market capitalization of LAVA Therapeutics N.V. - Ordinary Shares?
The market capitalization of LAVA Therapeutics N.V. - Ordinary Shares is 42.33M
How many shares of LAVA Therapeutics N.V. - Ordinary Shares are outstanding?
LAVA Therapeutics N.V. - Ordinary Shares has 42M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.